Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12858469.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Infliximab, a chimeric anti-tumor necrosis factor-alpha monoclonal antibody, has been demonstrated to be efficient and safe in patients with active rheumatoid arthritis and in the management of severe bouts of Crohn's disease. However, the safety of infliximab has not been evaluated in patients infected with hepatitis B virus. We report the case of a 28-year-old woman, with a positive hepatitis B virus surface antigen, who developed fulminant hepatitis 2 weeks after receiving a second infliximab infusion for a refractory adult onset Still's disease.
Medical subject headings
- Antibodies, Monoclonal
- Antirheumatic Agents
- Hepatitis B
- Liver Failure
- Still's Disease, Adult-Onset